Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2024[IFRS]

(Amounts less than one million yen are rounded down to the nearest million yen.)

Consolidated financial results for the nine months ended December 31, 2024 (from April 1, 2024 to December 31, 2024)

(1) Consolidated results of operations

(Percentage figures represent changes from the same period of the previous fiscal year.)
Nine months ended	Revenue		Business contribution profit		Operating profit
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%
December 31, 2024	831,840	3.5	28,805	59.1	(18,458)	-
December 31, 2023	803,952	-	18,106	-	14,642	-

Nine months ended	Profit before tax		Profit for the period		Profit attributable to owners of the Company
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%
December 31, 2024	(28,537)	-	(13,242)	-	(13,399)	-
December 31, 2023	4,651	-	(4,435)	-	(4,148)	-

Nine months ended	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2024	(27.09)	(27.09)
December 31, 2023	(8.39)	(8.37)

(Note)

“Business contribution profit” is calculated by deducting the cost of sales and selling, general and administrative expenses from revenue.
Total comprehensive income for the nine months ended December 31, 2024 and 2023, was (1,989) million yen and 21,518 million yen (a decrease of 32.1% year-on-year), respectively.
Basic earnings per share and diluted earnings per share are calculated based on the profit attributable to owners of Konica Minolta, Inc. (the “Company”).
The Precision Medicine Business is classified as a discontinued operation from the nine months ended December 31, 2024. As a result, revenue, business contribution profit, operating profit, and profit before tax represent the amount of continuing operations excluding the discontinued operation. Profit for the period and profit attributable to owners of the Company represent the sum of continuing operations and the discontinued operation. In addition, the changes from the previous fiscal year are not provided since the same reclassification has been made for the nine months ended December 31, 2023

(2) Consolidated financial position

As of	Total assets	Total equity	Equity attributable to owners of the Company	Equity ratio attributable to owners of the Company
As of	Millions of yen	Millions of yen	Millions of yen	%
December 31, 2024	1,382,798	548,972	535,312	38.7
March 31, 2024	1,388,052	553,382	539,816	38.9

2. Dividends per share

	End of the three-month period	End of the six-month period	End of the nine-month period	End of the year	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2024	-	0.00	-	5.00	5.00
Fiscal year ending March 31, 2025	-	0.00	-
Fiscal year ending March 31, 2025 (forecast)				0.00	0.00

(Note)Changes from the latest dividend forecasts: None

3. Consolidated forecasts for the fiscal year ending March 31, 2025 (from April 1, 2024 to March 31, 2025)

(Percentage figures represent changes from the previous fiscal year.)
Fiscal year ending	Revenue		Business contribution profit		Operating profit		Profit attributable to owners of the Company		Basic earnings per share
Fiscal year ending	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
March 31, 2025	1,134,000	2.4	42,000	26.0	(14,000)	－	0	-100.0	0.00

(Notes)

Changes from the latest consolidated forecasts: None
The Precision Medicine Business is classified as a discontinued operation from the nine months ended December 31, 2024. As a result, in the consolidated forecasts for the fiscal year ending March 31, 2025, revenue, business contribution profit, and operating profit represent the amount of continuing operations excluding the discontinued operation, and profit attributable to owners of the Company and basic earnings per share represent the sum of continuing operations and the discontinued operation. In addition, the changes from the previous fiscal year have been calculated using the retrospectively revised figures associated with the classification of the discontinued operation.

■ Notes

Significant changes in the scope of consolidation for the nine months ended December 31, 2024: Yes
Included: - (-)

Excluded: Two companies Invicro, LLC and Konica Minolta Business Associates Co., Ltd.
Changes in accounting policies or changes in accounting estimates
a. Changes in accounting policies required by International Financial Reporting Standards (IFRS): None

b. Changes in accounting policies other than the above a.: None

c. Changes in accounting estimates: Yes
Number of issued and outstanding shares (common stock)
a. Number of issued and outstanding shares (including treasury shares)
    As of December 31, 2024: 502,664,337 shares
    As of March 31, 2024: 502,664,337 shares

b. Number of treasury shares
    As of December 31, 2024: 7,846,129 shares
    As of March 31, 2024: 8,180,129 shares

c. Average number of issued and outstanding shares during the period
    The nine months ended December 31, 2024: 494,697,521 shares
    The nine months ended December 31, 2023: 494,243,888 shares

(Note)The Company has established the Board Incentive Plan. The shares owned by the trust account relating to this trust are accounted for as treasury shares (1,956,064 shares as of December 31 2024 , and 2,223,585 shares as of March 31, 2024).

■ Review procedures performed by certified public accountants or an audit firm for the attached quarterly consolidated financial statements: None

■ Explanation concerning the appropriate use of the forecasts for results of operations and other special matters

(Note on the forecasts for the consolidated financial results)

The forecasts for results of operations in this report are based on information currently available to the Company and its subsidiaries (the “Group”) and certain assumptions determined to be reasonable, and are not intended to assure any achievement of the Group’s operations. Actual results may differ significantly from the forecasts due to various factors. For further details of the assumptions that form the basis of the forecasts and other related matters when referring to the forecasts, refer to “1. OVERVIEW OF FINANCIAL RESULTS, (3) Explanation Regarding the Forecasts for the Consolidated Financial Results” in the attached Supplementary Information on page 15.

(Supplementary information for the quarterly financial results and briefing on the quarterly financial results)

The Company will hold a briefing on the quarterly financial results for institutional investors on Thursday, February 6, 2025. The proceedings and details of the briefing, along with the supplementary information on the quarterly financial results to be presented at the briefing, will be posted on the website of the Group soon after the briefing.

(Disclosure of the quarterly financial results, including the interim review report)

The Company plans to disclose the quarterly financial results, including the interim review report on Thursday, February 13, 2025.